588 related articles for article (PubMed ID: 22948877)
1. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
[TBL] [Abstract][Full Text] [Related]
2. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.
Espinel-Ingroff A; Chowdhary A; Cuenca-Estrella M; Fothergill A; Fuller J; Hagen F; Govender N; Guarro J; Johnson E; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; Trilles L; Kidd S; Turnidge J
Antimicrob Agents Chemother; 2012 Jun; 56(6):3107-13. PubMed ID: 22391546
[TBL] [Abstract][Full Text] [Related]
3. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
4. Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility.
Lee GA; Arthur I; Merritt A; Leung M
Med Mycol; 2019 Nov; 57(8):1004-1010. PubMed ID: 30649538
[TBL] [Abstract][Full Text] [Related]
5. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.
Espinel-Ingroff A; Chowdhary A; Gonzalez GM; Guinea J; Hagen F; Meis JF; Thompson GR; Turnidge J
Antimicrob Agents Chemother; 2015 Jan; 59(1):666-8. PubMed ID: 25313209
[TBL] [Abstract][Full Text] [Related]
6. Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility.
Lockhart SR; Iqbal N; Bolden CB; DeBess EE; Marsden-Haug N; Worhle R; Thakur R; Harris JR;
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):144-8. PubMed ID: 22494557
[TBL] [Abstract][Full Text] [Related]
7. High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the
Yang C; Bian Z; Blechert O; Deng F; Chen H; Li Y; Yang Y; Chen M; Zhan P
Front Cell Infect Microbiol; 2021; 11():723251. PubMed ID: 34790585
[TBL] [Abstract][Full Text] [Related]
8. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
[TBL] [Abstract][Full Text] [Related]
9. Molecular epidemiology and antifungal susceptibility profiles of clinical
Bandalizadeh Z; Shokohi T; Badali H; Abastabar M; Babamahmoudi F; Davoodi L; Mardani M; Javanian M; Cheraghmakani H; Sepidgar AA; Badiee P; Khodavaisy S; Afshari SAK; Ahmadikia K; Seyedmousavi S
J Med Microbiol; 2020 Jan; 69(1):72-81. PubMed ID: 31750814
[No Abstract] [Full Text] [Related]
10. Molecular typing of clinical isolates of Cryptococcus neoformans/Cryptococcus gattii species complex from Northeast Mexico.
González GM; Casillas-Vega N; Garza-González E; Hernández-Bello R; Rivera G; Rodríguez JA; Bocanegra-Garcia V
Folia Microbiol (Praha); 2016 Jan; 61(1):51-6. PubMed ID: 26109075
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel hybrids between Cryptococcus neoformans var. grubii VNI and Cryptococcus gattii VGII.
Aminnejad M; Diaz M; Arabatzis M; Castañeda E; Lazera M; Velegraki A; Marriott D; Sorrell TC; Meyer W
Mycopathologia; 2012 Jun; 173(5-6):337-46. PubMed ID: 22081254
[TBL] [Abstract][Full Text] [Related]
12. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Hagen F; Hare Jensen R; Meis JF; Arendrup MC
Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
[TBL] [Abstract][Full Text] [Related]
14. Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil.
Grizante Barião PH; Tonani L; Cocio TA; Martinez R; Nascimento É; von Zeska Kress MR
Mycoses; 2020 Dec; 63(12):1341-1351. PubMed ID: 32869413
[TBL] [Abstract][Full Text] [Related]
15. Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.
Carvajal SK; Melendres J; Escandón P; Firacative C
Microbiol Spectr; 2023 Aug; 11(4):e0140323. PubMed ID: 37341584
[TBL] [Abstract][Full Text] [Related]
16. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
[TBL] [Abstract][Full Text] [Related]
17. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.
Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Jones RN
Diagn Microbiol Infect Dis; 2011 Nov; 71(3):252-9. PubMed ID: 21917395
[TBL] [Abstract][Full Text] [Related]
18. Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Pfaller MA; Bustamante B; Canton E; Fothergill A; Fuller J; Gonzalez GM; Lass-Flörl C; Lockhart SR; Martin-Mazuelos E; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Szeszs MW; St-Germain G; Bonfietti LX; Guarro J; Turnidge J
Antimicrob Agents Chemother; 2014; 58(4):2006-12. PubMed ID: 24419346
[TBL] [Abstract][Full Text] [Related]
19. Molecular typing and antifungal susceptibility of clinical isolates of Cryptococcus neoformans and Cryptococcus gattii species complexes from the National Invasive Fungal Surveillance Network of Uruguay.
Puime CA; Bórmida V; Pan D
Med Mycol; 2023 Jul; 61(7):. PubMed ID: 37336574
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil.
Andrade-Silva L; Ferreira-Paim K; Mora DJ; Da Silva PR; Andrade AA; Araujo NE; Pedrosa AL; Silva-Vergara ML
Med Mycol; 2013 Aug; 51(6):635-40. PubMed ID: 23343452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
